- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | -2.14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2024 (4) | -1.56 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (3) | -1.17 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | -0.41 | 33.87 | 14.58 | -0.51 | 22.73 | 8.93 | -0.41 | 80.84 | 14.58 |
| 25Q4 (7) | -0.62 | -24.0 | -148.0 | -0.66 | -22.22 | -112.9 | -2.14 | -38.96 | -37.18 |
| 25Q3 (6) | -0.50 | 10.71 | 1.96 | -0.54 | -17.39 | -28.57 | -1.54 | -48.08 | -17.56 |
| 25Q2 (5) | -0.56 | -16.67 | -33.33 | -0.46 | 17.86 | -4.55 | -1.04 | -116.67 | -30.0 |
| 25Q1 (4) | -0.48 | -92.0 | 0.0 | -0.56 | -80.65 | 0.0 | -0.48 | 69.23 | 0.0 |
| 24Q4 (3) | -0.25 | 50.98 | 0.0 | -0.31 | 26.19 | 0.0 | -1.56 | -19.08 | 0.0 |
| 24Q3 (2) | -0.51 | -21.43 | 0.0 | -0.42 | 4.55 | 0.0 | -1.31 | -63.75 | 0.0 |
| 24Q2 (1) | -0.42 | 0.0 | 0.0 | -0.44 | 0.0 | 0.0 | -0.80 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.01 | -92.3 | 226.31 | 0.2 | 1191.6 | 0.19 | N/A | 本月係租賃及勞務收入增加;本年主係銷售醫療器材之收入增加所致 | ||
| 2026/3 | 0.17 | 2443.9 | 4171.96 | 0.18 | 1537.34 | 0.18 | 0.0 | 係銷售醫療器材之收入 | ||
| 2026/2 | 0.01 | 1.06 | 80.7 | 0.01 | 84.26 | 0.02 | 0.0 | 係租賃及勞務收入增加所致 | ||
| 2026/1 | 0.01 | -3.66 | 88.0 | 0.01 | 88.0 | 0.02 | 0.0 | 係租賃及勞務收入增加所致 | ||
| 2025/12 | 0.01 | 6.22 | -44.33 | 0.1 | -61.92 | 0.02 | 2.47 | 主係臨床前試驗勞務收入減少所致 | ||
| 2025/11 | 0.01 | -7.61 | 42.88 | 0.1 | -62.74 | 0.02 | 2.5 | 主係臨床前試驗勞務收入減少所致 | ||
| 2025/10 | 0.01 | 4.66 | -91.45 | 0.09 | -64.58 | 0.04 | 1.31 | 係臨床前試驗勞務收入減少所致 | ||
| 2025/9 | 0.01 | -72.94 | -84.76 | 0.08 | -52.21 | 0.04 | 1.34 | 係臨床前試驗勞務收入減少所致 | ||
| 2025/8 | 0.02 | 308.3 | 2571.73 | 0.08 | -41.56 | 0.05 | 1.09 | 係勞務收入增加所致 | ||
| 2025/7 | 0.01 | -60.42 | -92.56 | 0.05 | -59.71 | 0.04 | 1.31 | 係臨床前試驗勞務收入減少所致 | ||
| 2025/6 | 0.02 | -10.63 | -70.46 | 0.05 | -8.03 | 0.04 | 1.38 | 係臨床前試驗勞務收入減少所致 | ||
| 2025/5 | 0.02 | 326.56 | 0.0 | 0.03 | 0.0 | 0.02 | 2.0 | 本月係臨床前試驗勞務收入增加;本年係臨床前試驗勞務收入及租賃收入增加所致 | ||
| 2025/4 | 0.0 | 0.75 | 0.0 | 0.02 | 0.0 | 0.01 | 4.3 | 主係租賃收入增加所致 | ||
| 2025/3 | 0.0 | 7.6 | 0.0 | 0.01 | 0.0 | 0.0 | N/A | 主係租賃收入增加所致 | ||
| 2025/2 | 0.0 | 5.14 | 0.0 | 0.01 | 0.0 | 0.0 | N/A | 係租賃收入增加所致 | ||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
免責聲明
本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。